Beruflich Dokumente
Kultur Dokumente
Research Question:
There are currently 7 approved Angiotension Receptor Blocker (ARB) in the market and joining
the lineup is the new Azilsartan Medoxomil as the 8th ARB. The main question does azilsartan have
distinguishing features that should motivate choosing it over any of the other sartans for use in clinical
practice?
Citation
Bakris GL, Sica D, Weber MA, et al. The comparative effects of azilsartan medoxomil and olmesartan on
ambulatory and clinic blood pressure. J Clin Hypertension (Greenwich). 2011;13:8188.
Clinical Characteristics of the Study
1. Population
Inclusion Cirteria
1. Men or women > 18 years old
2. Diagnosed with primary hypertension (SBP > 150mmHg and <180 mmHg and 24 hour mean
SBP >130mmHg and <170 mmHg
3. Screening laboratory test were within the reference range
Exclusion Criteria
1. Sitting clinic diastolic BP (DBP) >114mmHg
2. History of major cardiovascular events, significant cardiac conduction defects, secondary
hypertension
3.
4.
5.
6.
7.
8.
9.
2. Interventions Compared
Azilsartan Medoxomil 20mg, 40mg and 80mg OD versus Olmesartan Medoxomil 40mg
OD and placebo.
3. Outcomes Monitored
Primary Endpoints
a. Change in 24 hour mean systolic BP at week 6
Secondary Endpoints
a. Change in trough sitting clinic systolic BP at week 6
b. Change from baseline 24 hour mean DBP by ABPM
Definition of Terms
1. Primary Hypertension
Study Validity
1. Were the patients randomly assigned to treatment groups?
Yes, the study randomized eligible patients after a 2week placebo controlled run-in trial with a
total of 1275 patients assigned to different groups.
2. Was allocation concealed?
3.
4.
5.
6.
7.
8.
9.
Yes, the study design was randomized, multicenter, parallel group, double-blind.
Were baseline characteristics similar at the start of the trial
Were patient, caregivers, study personnel blinded to treatment assignment?
Were all patients analyzed under the groups to which they were originally randomized?
Was follow-up adequate?
Aside from the experimental intervention were the groups treated equally?
How large was the treatment effect
Were all clinically important adverse effect considered?
II. Results
Authors Conclusion
The study suggest that Azilsartan Medoxomil 80mg is more effective in reducing SBP than the
higest approved does of Olmesartan Medoxomil, which is considred to be more effective than
others in the ARB class.
Reviewers Concluson